Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    • News

  • DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    • News

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

Landmark moment for Proteomics’s PromarkerD as it gets published in the UK’s NICE advice

  • In News
  • December 14, 2022
  • Alinda Gupta
Landmark moment for Proteomics’s PromarkerD as it gets published in the UK’s NICE advice

In the mood for some NICE advice? Here goes: The UK’s National Institute for Health and Care Excellence (NICE) has published a MedTech Innovation Briefing on PromarkerD, i.e. a predictive blood test determining diabetes kidney disease (DKD).

The Briefing, dubbed NICE advice, reports that PromarkerD is effective at predicting renal function decline in people with type 2 diabetes. 

This is a prestigious moment for Perth-based medical tech company Proteomics International (ASX: PIQ), the parent company of PromarkerD. NICE advice is a super popular and selective publication in the UK. It has a rigorous selection process that accounts for the potential benefits of a technology, its regulatory status, clinical evidence and more. This year, only 29 Medtech Innovation Briefings have been published, and PromarkerD is one of them. 

Proteomics International Managing Director, Dr Richard Lipscombe, commented, “Selection of the test as an innovative technology worthy of NICE advice is an important step towards [the] future recommendation for clinical use of PromarkerD in the UK.”

NICE is an independent organisation established by the UK Government to provide national guidance and advice on medical treatments. These briefings, commissioned by the NHS (National Health Service), are basically documents geared towards assisting the UK’s healthcare workers, patients and clinicians. They also create awareness of new technologies for planning and commissioning new innovations in the UK healthcare industry.  

Lipscombe detailed, “The Medtech Innovation Briefing provides objective information to help doctors make the best clinical decisions for their patients. The NICE advice supports the reimbursement process and broader adoption of PromarkerD in the UK, and its publication enables us to pursue inclusion of PromarkerD in the NICE Guidelines and to engage with the NHS Supply Chain Tender process.”

Over four million adults in the UK live with diabetes and an additional 3 million with pre-diabetes. The country is a significant market opportunity for PromarkerD. Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The test is already registered for use with the UK Medicines & Healthcare products Regulatory Agency.

Upon assessing PromarkerD, independent experts appointed by NICE found that the technology is novel and is expected to be used in addition to standard care tests. PromarkerD may allow for the early identification of high-risk patients, thus altering and hopefully improving their treatment course. Ultimately, this could lead to a decrease in the number of people developing end-stage renal disease, reducing hospitalisation and the need for dialysis. 

By securing a spot in the Medtech Briefings, Proteomics gains credibility that can help it reach a vast array of healthcare practitioners. Given that these briefings are referred by the broader healthcare industry in the country, it will allow for networking with private healthcare providers beyond the NHS. 

At the time of writing, NICE has withdrawn the briefing to correct factual errors in the text.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  •  
  •  
  •  
  •  
  • asx piq
  • medtech
  • piq
  • promarkerd
  • Proteomics
  • richard lipscombe
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.